Impact of Prasterone on Cardiometabolic Indicators in Perimenopausal Women.

Summary

Perimenopause is the natural transition period towards menopause, in which the ovarian reserve begins to decrease, and the woman loses her fertility. It usually starts around the age of 40 and has a variable duration. It has been identified that the decrease in estrogen levels leads to the development of metabolic and cardiovascular complications, such as metabolic syndrome. Dehydroepiandrosterone (DHEA) is a hormone that converts to testosterone and estrogen and is mainly associated with age-related changes in cardiovascular tissues and metabolism, among others. This hormone declines with age, contributing to the development of age-related disorders, such as cardiovascular disease. In theory, DHEA has beneficial effects in regulating glucose and lipid metabolism and in ameliorating obesity. It is hypothesized that DHEAS and cardiovascular disease may share causal pathways, for example, nitric oxide synthesis and endothelial cell damage. In addition, it has been observed that the administration of DHEA significantly reduces the level of triglycerides and improves insulin sensitivity. There are few studies focused on the perimenopause stage and none of them focused on the prevention of cardiometabolic risk. Therefore, evaluating the impact of prasterone on cardiometabolic indicators in premenopausal women is essential.

Timeline

Start

2020-01-10

Primary completion

2020-12-20

Completion

2021-01-10

Publications

• Background Rabijewski M, Papierska L, Binkowska M, Maksym R, Jankowska K, Skrzypulec-Plinta W, Zgliczynski W. Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women - position statement of expert panel of Polish Menopause and Andropause Society. Ginekol Pol. 2020;91(9):554-562. doi: 10.5603/GP.2020.0091.
• Background Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG, Hirschberg AL, Kiesel L, Lopes P, Pines A, van Trotsenburg M, Lambrinoudaki I, Rees M. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020 May;135:82-88. doi: 10.1016/j.maturitas.2020.03.007. Epub 2020 Mar 16.
• Background Teixeira CJ, Veras K, de Oliveira Carvalho CR. Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period. J Mol Med (Berl). 2020 Jan;98(1):39-57. doi: 10.1007/s00109-019-01842-5. Epub 2019 Nov 12.
• Background Vegunta S, Kling JM, Kapoor E. Androgen Therapy in Women. J Womens Health (Larchmt). 2020 Jan;29(1):57-64. doi: 10.1089/jwh.2018.7494. Epub 2019 Nov 5.
• Background Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020 Jan;153:108507. doi: 10.1016/j.steroids.2019.108507. Epub 2019 Oct 3.
• Background Teixeira CJ, Ribeiro LM, Veras K, da Cunha Araujo LC, Curi R, de Oliveira Carvalho CR. Dehydroepiandrosterone supplementation is not beneficial in the late postmenopausal period in diet-induced obese rats. Life Sci. 2018 Jun 1;202:110-116. doi: 10.1016/j.lfs.2018.03.052. Epub 2018 Mar 27.
• Background Oh H, Wild RA, Manson JE, Bea JW, Shadyab AH, Pfeiffer RM, Saquib N, Underland L, Anderson GL, Xu X, Trabert B. Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2018-2029. doi: 10.1158/1055-9965.EPI-21-0604. Epub 2021 Aug 26.
• Background Tang J, Chen LR, Chen KH. The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview. Pharmaceuticals (Basel). 2021 Dec 29;15(1):46. doi: 10.3390/ph15010046.
• Background Martinez-Garcia G, Rodriguez-Ramos M, Santos-Medina M, Mata-Cuevas LA, Carrero-Vazquez AM, Chipi-Rodriguez Y. Triglyceride-glucose index impact on in-hospital mortality in acute myocardial infarction. Results from the RECUIMA multicenter registry. Gac Med Mex. 2022;158(2):83-89. doi: 10.24875/GMM.M22000646.
• Background Lu Y, Liu S, Qiao Y, Li G, Wu Y, Ke C. Waist-to-height ratio, waist circumference, body mass index, waist divided by height0.5 and the risk of cardiometabolic multimorbidity: A national longitudinal cohort study. Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2644-2651. doi: 10.1016/j.numecd.2021.05.026. Epub 2021 Jun 4.
• Background Liu X, Wu Q, Yan G, Duan J, Chen Z, Yang P, Bragazzi NL, Lu Y, Yuan H. Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype. J Endocrinol Invest. 2021 Jun;44(6):1253-1261. doi: 10.1007/s40618-020-01417-z. Epub 2020 Sep 9.
• Background Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Association of endogenous DHEA/DHEAS with coronary heart disease: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2019 Nov;46(11):984-994. doi: 10.1111/1440-1681.13146. Epub 2019 Aug 29.
• Background Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015 Jan 1;438:274-8. doi: 10.1016/j.cca.2014.08.042. Epub 2014 Sep 6.
• Background Baez-Duarte BG, Zamora-Ginez I, Rodriguez-Ramirez SO, Pesqueda-Cendejas LK, Garcia-Aragon KH. TG/HDL index to identify subjects with metabolic syndrome in the Mexican population. Gac Med Mex. 2022;158(5):259-264. doi: 10.24875/GMM.M22000693.
• Background Farinola MG, Sganga M. [Cut-off points of anthropometric markers for hypertension and hyperglycemia in Argentine adults: a cross-sectional study from the 4th ENFR]. Rev Fac Cien Med Univ Nac Cordoba. 2022 Sep 16;79(3):260-266. doi: 10.31053/1853.0605.v79.n3.37313. Spanish.
• Background Qiao T, Luo T, Pei H, Yimingniyazi B, Aili D, Aimudula A, Zhao H, Zhang H, Dai J, Wang D. Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study. Cardiovasc Diabetol. 2022 Nov 1;21(1):225. doi: 10.1186/s12933-022-01670-x.
• Background Vega-Cardenas M, Flores-Sanchez J, Torres-Rodriguez ML, Sanchez-Armass Capello O, Vargas-Morales JM, Cossio-Torres PE, Teran-Garcia M, Aradillas-Garcia C. [Distribution of triglycerides and glucose (TyG) index and homeostasis model assessment insulin resistance for the evaluation of insulin sensitivity on late adolescence in Mexicans]. Nutr Hosp. 2022 Dec 20;39(6):1349-1356. doi: 10.20960/nh.04120. Spanish.

Drugs

Indications